SPAC

Amid a disciplined SPAC market resurgence, Samos Energy's new fund targets cash-generating assets, signaling a strategic pivot back to energy security.

Led by a serial SPAC sponsor, Mercator Acquisition Corp. tests a cautious market, targeting tech disruptors in finance and real estate. Is this the new model?

Freedom Metals Acquisition Corp. launches a $275M IPO, betting on the high-stakes critical minerals sector in a newly disciplined SPAC market.

Ares Management's third blank-check company enters a disciplined SPAC landscape, signaling a strategic shift for investors and the innovative companies it will hunt.

As Cartesian Growth Corp IV launches its IPO, it's not just another blank check. It’s a test case for a new, disciplined era of strategic acquisitions.

In a rare show of confidence, 85% of SPAC shareholders back a merger with solid-state battery maker ProLogium, unlocking $156.8M for a tech powering EVs and AI.

As Forefront Tech's shares and warrants begin separate trading, the move is more than procedural—it signals a maturing search for a tech target in Southeast Asia.

Amid a resurgent SPAC market, Wilco 63 launches a $200M hunt for a tech unicorn in AI and robotics. Can it navigate a landscape that now values execution over hype?

The newly formed SPAC, led by veterans of sports finance and investment banking, is targeting acquisitions in sports, eSports, and entertainment.

Modular home pioneer BOXABL is on the verge of going public. We look at the $3.5B deal, the SPAC risks, and its potential to disrupt the housing market.

Amid a rebounding SPAC market, Tribeca Strategic Acquisition Corp. launches with a unique structure, aiming its $140M war chest at high-growth private companies.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

The blank-check firm's successful debut signals renewed, selective investor appetite for SPACs with a sharp focus on high-growth Israeli technology.

With a fresh $60 million IPO, JATT II is targeting the next wave of healthcare innovators using AI and machine learning to revolutionize drug discovery.